Business
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032
SAN DIEGO, Nov. 6, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), today announced the pricing of $650 million
About this update from Halozyme Therapeutics, Inc.
[{"type":"text","content":"\n SAN DIEGO, Nov. 6, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (\"Halozyme\" or the \"Company\"), today announced the pricing of $650 million aggregate principal amount of 0% convertible senior notes due 2031 (the \"2031 Notes\") and $650 million aggregate principal amount of 0.875% convertible senior notes due 2032 (the \"2032 Notes\" and, together with the 2031 Notes, the \"Convertible Notes\"). The Company also granted a 13-day option to the initial purchasers to purchase up to an additional $100 million aggregate principal amount of the 2031 Notes and up to an additional $100 million aggregate principal amount of the 2032 Notes. The Convertible Notes are being offered and sold only to persons reasonably believed to be \"qualified institutional buyers\" pursuant to Rule 144A under the Securities Act of 1933, as amended (the \"Securities Act\").\n The 2031 Notes will be senior, unsecured obligations of the Company. The 2031 Notes will not bear regular interest, and the principal amount of the 2031 Notes will not accrete. The 2032 Notes will be senior, unsecured obligations of the Company and will accrue interest payable semi-annually in arrears at an annual rate of 0.875%. The 2031 Notes have an initial conversion rate of 11.4683 shares of the Company's common stock per $1,000 principal amount of 2031 Notes (which is equivalent to an initial conversion price of approximately $87.20 per share of the Company's common stock, representing an initial conversion premium of approximately 27.5% above the closing price of $68.39 per share of the Company's common stock on November 6, 2025). The 2032 Notes have an initial conversion rate of 11.4683 shares of the Company's common stock per $1,000 principal amount of 2031 Notes (which is equivalent to an initial conversion price of approximately $87.20 per share of the Company's common stock, representing an initial conversion premium of approximately 27.5% above the closing price of $68.39 per share of the Company's common stock on November 6, 2025). Each conversion rate for the 2031 Notes and 2032 Notes, respectively, is subject to adjustment in some events but will not be adjusted for any accrued and unpaid special and additional interest with respect to the 2031 Notes and accrued and unpaid interest with respect to the 2032 Notes. Holders of the Convertible Notes...